Angiotech partner announces European approval for world's first "next-generation" drug-eluting stent system
08 September 2005 - 6:18PM
PR Newswire (US)
TAXUS(R) Liberte receives CE Mark VANCOUVER, Sept. 8
/PRNewswire-FirstCall/ -- Angiotech Pharmaceuticals, Inc.
(NASDAQ:ANPINASDAQ:TSX:NASDAQ:ANP) corporate partner Boston
Scientific Corporation ("BSC") today announced that it has received
CE Mark for its TAXUS(R) Liberte(TM) paclitaxel-eluting stent
system, the world's first "next- generation" drug- eluting stent
system. BSC plans to launch the product in European markets and
other key CE Mark-dependent international markets immediately.
TAXUS Liberte was launched earlier this year in select
international markets and is expected to launch in the United
States in 2006. "We are very pleased to receive European approval
for our next-generation drug-eluting stent system," said Paul
LaViolette, Chief Operating Officer of Boston Scientific. "The
TAXUS Liberte stent system is designed to improve deliverability
and conformability, providing physicians with state-of-the-art
stent performance coupled with proven paclitaxel-eluting
technology. We are delighted that European physicians and patients
can now benefit from this highly advanced technology for the
treatment of coronary artery disease." "The TAXUS Liberte stent
system combines the new Liberte stent platform with the
unparalleled rigor of the TAXUS clinical program," said John
Ormiston, M.D., interventional cardiologist at Mercy Hospital and
the Green Lane Cardiovascular Unit of the Auckland City Hospital,
Auckland, New Zealand. "The TAXUS Liberte system offers enhanced
ability to deliver across complex lesions, especially for patients
with complex anatomies and tortuous lesions, and is designed to
provide uniform drug delivery." TAXUS Liberte is the first
drug-eluting coronary stent system to incorporate a next-generation
stent platform. The Liberte stent features the Veriflex(TM) stent
design, an extremely flexible cell geometry with thin struts and
uniform strut distribution. This new platform has been designed to
offer improved deliverability and conformability in challenging
anatomy. TAXUS Liberte also features the enhanced TrakTip(TM)
catheter tip, mounted on the Maverick(2)(TM) delivery catheter, to
provide better lesion crossability. In addition, the TrakTip
catheter tip has a low lesion-entry profile, also intended to
further improve crossability. BSC received the CE Mark for the bare
metal Liberte stent system in December 2003 while U.S. Food and
Drug Administration approval was granted for the bare-metal version
of the Liberte stent in January of this year. In May, BSC announced
thirty-day safety data from its ATLAS pivotal study, designed to
support U.S. FDA approval of the TAXUS Liberte stent system. BSC's
first-generation drug-eluting stent system, the TAXUS(R)
Express(2)(TM) paclitaxel-eluting coronary stent system, is the
worldwide leader in the coronary stent market. The TAXUS Express(2)
system is supported by the most comprehensive randomized,
controlled clinical program of any drug- eluting stent system. BSC
acquired worldwide exclusive rights from Angiotech to use
paclitaxel to coat its coronary stent products and has co-exclusive
rights to other vascular and non-vascular products. Vancouver-based
Angiotech Pharmaceuticals, Inc. is a specialty pharmaceutical
company pioneering the combination of pharmaceutical compounds with
medical devices and biomaterials to both create novel solutions for
poorly addressed disease states and dramatically improve surgical
outcomes. To find out more about Angiotech Pharmaceuticals, Inc.
(NASDAQ:ANPINASDAQ:TSX:NASDAQ:ANP), please visit our website at
http://www.angiotech.com/. Statements contained herein that are not
based on historical or current fact, including without limitation
statements containing the words "anticipates," "believes," "may,"
"continue," "estimate," "expects," "may" and "will" and words of
similar import, constitute "forward-looking statements" within the
meaning of the U.S. Private Securities Litigation Reform Act of
1995. Such forward-looking statements involve known and unknown
risks, uncertainties and other factors that may cause the actual
results, events or developments to be materially different from any
future results, events or developments expressed or implied by such
forward-looking statements. Such factors include, among others, the
following: general economic and business conditions, both
nationally and in the regions in which the Company operates;
technology changes; competition; changes in business strategy or
development plans; the ability to attract and retain qualified
personnel; existing governmental regulations and changes in, or the
failure to comply with, governmental regulations; liability and
other claims asserted against the Company; and other factors
referenced in the Company's filings with the United States
Securities and Exchange Commission or the Canadian securities
regulators. Given these uncertainties, readers are cautioned not to
place undue reliance on such forward-looking statements. The
Company does not assume the obligation to update any
forward-looking statements. Company Contacts: Todd Young, Vice
President, Investor Relations and Communications Angiotech
Pharmaceuticals (604) 221-7676 ext 6933 Rui Avelar, Senior Vice
President, Medical Affairs and Communications Angiotech
Pharmaceuticals, Inc (604) 221-7676 ext 6996 Media Relations: Wendy
Carhart Waggener Edstrom Bioscience (503) 443-7354 email:
DATASOURCE: Angiotech Pharmaceuticals, Inc. CONTACT: Company
Contacts: Todd Young, Vice President, Investor Relations and
Communications, Angiotech Pharmaceuticals, (604) 221-7676 ext 6933;
Rui Avelar, Senior Vice President, Medical Affairs and
Communications, Angiotech Pharmaceuticals, Inc, (604) 221-7676 ext
6996; Media Relations: Wendy Carhart, Waggener Edstrom Bioscience,
(503) 443-7354, email:
Copyright
Angiotech Pharmaceuticals - Common Shares (MM) (NASDAQ:ANPI)
Historical Stock Chart
Von Jun 2024 bis Jul 2024
Angiotech Pharmaceuticals - Common Shares (MM) (NASDAQ:ANPI)
Historical Stock Chart
Von Jul 2023 bis Jul 2024